Cyclacel Pharmaceuticals, Inc. (CYCC)

Market Cap	5.61M
Revenue (ttm)	14,000
Net Income (ttm)	-8.35M
Shares Out	23.76M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,592,071
Open	0.2479
Previous Close	0.2479
Day's Range	0.2150 - 0.2500
52-Week Range	0.2150 - 39.8400
Beta	0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2025

About CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: CYCC
• Website: https://www.cyclacel.com

Financial Performance

In 2024, Cyclacel Pharmaceuticals's revenue was $43,000, a decrease of -89.76% compared to the previous year's $420,000. Losses were -$11.21 million, -50.73% less than in 2023.